Y ArpithaAnbu Deborah1, Madhumitha Haridoss2, Meenakumari Natarajan2, Vasna Joshua1, Bhavani Shankara Bagepally3,4. 1. ICMR-National Institute of Epidemiology, Tamil Nadu, Chennai, 600077, India. 2. HTA Resource Centre, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India. 3. HTA Resource Centre, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India. bshankara@gmail.com. 4. ICMR-National Institute of Epidemiology, Tamil Nadu, Chennai, 600077, India. bshankara@gmail.com.
Abstract
PURPOSE: Gallstone disease or cholelithiasis is a chronic illness that usually presents with pain in the abdomen, vomiting and indigestion leading to impaired quality of life. EQ-5D utility score is a validated measure of health-related quality of life (HRQoL). We systematically reviewed the literature and synthesised EQ-5D utility scores among patients with gallstone disease and its improvement on treatment. METHODS: We have systematically searched observational studies reporting EQ-5D utility scores of gallstone disease in PubMed, Scopus, and Embase databases, from inception until February 2021. We selected the studies adhering to the PRISMA guidelines. The selected studies were reviewed, and the EQ-5D utility values of pre and post cholecystectomy were pooled using the random-effects model. RESULT: From identified 4,817 records of database search, eleven studies predominantly from western countries with 2,189 participants were included for systematic review and meta-analysis. The pooled EQ-5D and visual analogue scores were 0.87 (0.82 to 0.91, I2 = 93.73%) and 83.30 (60.59 to 106.12, I2 = 99.30%) respectively with high heterogeneity. The pooled EQ-5D and EQ-5D visual analogue scores post cholecystectomy treatment were 0.93 (0.91 to 0.95, I2 = 90.17%) and 91.7 (85.99 to 96.35, I2 = 97.93%) respectively. The mean difference between the baseline and post intervention were 0.05 (0.01 to 0.10, I2 = 93.50%) and 10.58 (-8.63 to 29.79, I2 = 98.32%) for EQ-5D and visual analogue scores respectively with high heterogeneity between the studies. CONCLUSION: The pooled mean difference indicates improvement in HRQoL after cholecystectomy but with high heterogeneity. Further high-quality studies from Asian countries are required for globally representative quantification and precise estimates of HRQoL among gallstone diseases. PROSPERO REGISTRATION ID: CRD42021234467.
PURPOSE: Gallstone disease or cholelithiasis is a chronic illness that usually presents with pain in the abdomen, vomiting and indigestion leading to impaired quality of life. EQ-5D utility score is a validated measure of health-related quality of life (HRQoL). We systematically reviewed the literature and synthesised EQ-5D utility scores among patients with gallstone disease and its improvement on treatment. METHODS: We have systematically searched observational studies reporting EQ-5D utility scores of gallstone disease in PubMed, Scopus, and Embase databases, from inception until February 2021. We selected the studies adhering to the PRISMA guidelines. The selected studies were reviewed, and the EQ-5D utility values of pre and post cholecystectomy were pooled using the random-effects model. RESULT: From identified 4,817 records of database search, eleven studies predominantly from western countries with 2,189 participants were included for systematic review and meta-analysis. The pooled EQ-5D and visual analogue scores were 0.87 (0.82 to 0.91, I2 = 93.73%) and 83.30 (60.59 to 106.12, I2 = 99.30%) respectively with high heterogeneity. The pooled EQ-5D and EQ-5D visual analogue scores post cholecystectomy treatment were 0.93 (0.91 to 0.95, I2 = 90.17%) and 91.7 (85.99 to 96.35, I2 = 97.93%) respectively. The mean difference between the baseline and post intervention were 0.05 (0.01 to 0.10, I2 = 93.50%) and 10.58 (-8.63 to 29.79, I2 = 98.32%) for EQ-5D and visual analogue scores respectively with high heterogeneity between the studies. CONCLUSION: The pooled mean difference indicates improvement in HRQoL after cholecystectomy but with high heterogeneity. Further high-quality studies from Asian countries are required for globally representative quantification and precise estimates of HRQoL among gallstone diseases. PROSPERO REGISTRATION ID: CRD42021234467.
Authors: J L Frossard; A Hadengue; G Amouyal; A Choury; O Marty; E Giostra; F Sivignon; L Sosa; P Amouyal Journal: Gastrointest Endosc Date: 2000-02 Impact factor: 9.427
Authors: Farhaad C Golkar; Sharona B Ross; Steffanie Sperry; Michelle Vice; Kenneth Luberice; Natalie Donn; Connor Morton; Jonathan M Hernandez; Alexander S Rosemurgy Journal: Am J Surg Date: 2012-11 Impact factor: 2.565
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: J F Miquel; C Covarrubias; L Villaroel; G Mingrone; A V Greco; L Puglielli; P Carvallo; G Marshall; G Del Pino; F Nervi Journal: Gastroenterology Date: 1998-10 Impact factor: 22.682